Current progress in the pharmacological therapy of fibromyalgia

Expert Opinion on Investigational Drugs

Volumn 18, Issue 10, 2009, Pages 1479-1493

  Rao, Srinivas G ^a  

^a Cypress Bioscience Inc   (United States)

Author keywords

Dual reuptake inhibitors; Fatigue; Fibromyalgia; Milnacipran; Pain

Indexed keywords

AD 337; AGN 203818; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ARMODAFINIL; CASOPITANT; DOLASETRON MESILATE; DOPAMINE RECEPTOR STIMULATING AGENT; DULOXETINE; ESZOPICLONE; ETIRACETAM; FLUPIRTINE; GABAPENTIN; GROWTH HORMONE; HARKOSERIDE; IBUTAMOREN; MILNACIPRAN; NABILONE; NORADRENALIN; OXYBATE SODIUM; PLACEBO; PREGABALIN; PYRIDOSTIGMINE; QUETIAPINE; ROPINIROLE; ROTIGOTINE; SEROTONIN AGONIST; TERGURIDE; THREO 3,4 DIHYDROXYPHENYLSERINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZONISAMIDE;

ADD ON THERAPY; AGITATION; APPETITE; ATTENTION DISTURBANCE; BALANCE DISORDER; BLURRED VISION; CATAPLEXY; CLINICAL RESEARCH; CLINICAL TRIAL; COGNITIVE DEFECT; CONCENTRATION (PARAMETERS); CONSTIPATION; DAYTIME SOMNOLENCE; DECREASED APPETITE; DIABETIC NEUROPATHY; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG INHIBITION; DRUG MECHANISM; DRUG WITHDRAWAL; EPILEPSY; EUPHORIA; FATIGUE; FIBROMYALGIA; FOOD AND DRUG ADMINISTRATION; GENERALIZED ANXIETY DISORDER; HEADACHE; HEART PALPITATION; HEART RATE; HEREDITY; HOT FLUSH; HUMAN; HYPERHIDROSIS; HYPERTENSION; INSOMNIA; LIVER FUNCTION; MAJOR DEPRESSION; MORNING STIFFNESS; NARCOLEPSY; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; PAIN; PARESTHESIA; PERIPHERAL EDEMA; POSTHERPETIC NEURALGIA; PRESYNAPTIC NERVE; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; UPPER ABDOMINAL PAIN; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ANALGESICS; ANIMALS; CLINICAL TRIALS AS TOPIC; CYCLOPROPANES; DRUGS, INVESTIGATIONAL; FIBROMYALGIA; GAMMA-AMINOBUTYRIC ACID; HUMANS; SEROTONIN UPTAKE INHIBITORS; THIOPHENES;

EID: 70349308557     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903203771     Document Type: Review

References (130)

1. Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38(1):19-28
2. Clauw DJ, Chrousos GP. Chronic pain and fatigue syndromes: overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation 1997;4(3):134-153
3. Abeles M, Solitar BM, Pillinger MH, Abeles AM. Update on fibromyalgia therapy. Am J Med 2008;121(7):555-561
4. Mease PJ, Seymour K. Fibromyalgia: should the treatment paradigm be monotherapy or combination pharmacotherapy? Curr Pain Headache Rep 2008;12(6):399-405
5. Adler GK, Geenen R. Hypothalamic-pituitary-adrenal and autonomic nervous system functioning in fibromyalgia. Rheum Dis Clin North Am 2005;31(1):187-202 (Pubitemid 40082062)
6. Gur A, Oktayoglu P. Central nervous system abnormalities in fibromyalgia and chronic fatigue syndrome: new concepts in treatment. Curr Pharm Des 2008;14(13):1274-1294 (Pubitemid 351997822)
7. Clauw DJ. Pharmacotherapy for patients with fibromyalgia. J Clin Psychiatry 2008;69(Suppl 2):25-29
8. Ablin JN, Buskila D. Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs 2008;13(1):53-62
9. Lawson K. Pharmacological treatments of fibromyalgia: do complex conditions need complex therapies? Drug Discov Today 2008;13(7-8):333-340
10. Bradley LA. Pathophysiologic mechanisms of fibromyalgia and its related disorders. J Clin Psychiatry 2008;69(Suppl 2):6-13
11. Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 2002;46(5):1333-1343 (Pubitemid 34525843)
12. Cook DB, Lange G, Ciccone DS, et al. Functional imaging of pain in patients with primary fibromyalgia. J Rheumatol 2004;31(2):364-378 (Pubitemid 38160761)
13. Wood PB, Schweinhardt P, Jaeger E, et al. Fibromyalgia patients show an abnormal dopamine response to pain. Eur J Neurosci 2007;25(12):3576-3582 (Pubitemid 47020461)
14. Russell IJ. The promise of substance P inhibitors in fibromyalgia. Rheum Dis Clin North Am 2002;28(2):329-342
15. Dubner R, Hargreaves KM. The neurobiology of pain and its modulation. Clin J Pain 1989;5(Suppl 2):S1-6
16. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992;35(5):550-556
17. Stahl SM. The psychopharmacology of energy and fatigue. J Clin Psychiatry 2002;63(1):7-8
18. Staud R. Treatment of fibromyalgia and its symptoms. Expert Opin Pharmacother 2007;8(11):1629-1642
19. Martinez-Lavin M. Biology and therapy of fibromyalgia. Stress, the stress response system, and fibromyalgia. Arthritis Res Ther 2007;9(4):216
20. Harding SM. Sleep in fibromyalgia patients: subjective and objective findings. Am J Med Sci 1998;315(6):367-376 (Pubitemid 28285131)
21. Briand LA, Gritton H, Howe WM, et al. Modulators in concert for cognition: modulator interactions in the prefrontal cortex. Prog Neurobiol 2007;83(2):69-91 (Pubitemid 47464694)
22. Hudson JI, Arnold LM, Keck PE Jr, et al. Family study of fibromyalgia and affective spectrum disorder. Biol Psychiatry 2004;56(11):884-891 (Pubitemid 39575463)
23. Heils A, Teufel A, Petri S, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996;66(6):2621-2624 (Pubitemid 26159101)
24. Cohen H, Buskila D, Neumann L, Ebstein RP. Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5- HTTLPR) polymorphism, and relationship to anxiety-related personality traits. Arthritis Rheum 2002;46(3):845-847 (Pubitemid 34214272)
25. Offenbaecher M, Bondy B, de Jonge S, et al. Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum 1999;42(11):2482-2488 (Pubitemid 30333429)
26. Gürsoy S, Erdal E, Herken H, et al. Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome. Rheumatol Int 2003;23(3):104-107 (Pubitemid 36712983)
27. Vargas-Alarcón G, Fragoso JM, Cruz-Robles D, et al. Catechol-O-methyltransferase gene haplotypes in Mexican and Spanish patients with fibromyalgia. Arthritis Res Ther 2007;9(5):R110 (Pubitemid 350226899)
28. Buskila D, Cohen H, Neumann L, Ebstein RP. An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits. Mol Psychiatry 2004;9(8):730-731 (Pubitemid 39107962)
29. Wolfe F, Smythe HA, Yunus MB, et al. The American college of rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum 1990;33(2):160-172 •• Publication of the primary criteria for FM classification for the purpose of inclusion of patients into clinical trials.
30. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Suppl 2005;32(Suppl 75):6-21 • Publication discussing FM diagnosis, clinical trial design, and outcome measures in FM. (Pubitemid 41113954)
31. Clauw DJ. Fibromyalgia: update on mechanisms and management. J Clin Rheumatol 2007;13(2):102-109
32. Mease P, Arnold LM, Bennett R, et al. Fibromyalgia syndrome. J Rheumatol 2007;34(6):1415-1425 • Publication reporting the FM syndrome workshop at OMERACT 8 that identifies and prioritizes symptom domains that should be consistently evaluated in FM clinical trials.
33. Tugwell P, Boers M, Brooks P, et al. OMERACT: an international initiative to improve outcome measurement in rheumatology. Trials 2007;8:38 (Pubitemid 46364017)
34. Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial. J Rheumatol 2009;36(2):398-409; correction 36(3):661 • A pivotal, Phase III, US registration clinical trial that established efficacy and tolerability of milnacipran for the management of FM.
35. Clauw DJ, Mease P, Palmer RH, et al. Milnacipran for the treatment of fibromyalgia in adults: a 15-week multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008;30(11):1988- 2004; correction 31(2):446 • A pivotal, Phase III, US registration clinical trial that established efficacy and tolerability of milnacipran for the management of FM.
36. Branco JC, Perrot S, Bragee G, et al. Milnacipran for the treatment of fibromyalgia syndrome: a European multicenter, randomized, double-blind, placebo-controlled trial. Ann Rheum Dis 2008;67(Suppl 2):251
37. Russell IJ, Perkins AT, Michalek JE. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum 2009;60(1):299-309
38. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52(4):1264-1273 (Pubitemid 40530135)
39. Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008;35(3):502-514
40. Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008;9(9):792-805 • A pivotal, Phase III, US registration clinical trial that established efficacy and Expert Opin. Investig. Drugs (2009) 18(10) tolerability of pregabalin for the management of FM.
41. Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain 2008;136(3):419-431 • A pivotal, Phase III, US registration clinical trial that established efficacy and tolerability of pregabalin for the management of FM.
42. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50(9):2974-2984 (Pubitemid 39209537)
43. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119(1-3):5-15 • A pivotal, Phase III, US registration clinical trial that established efficacy and tolerability of duloxetine for the management of FM. (Pubitemid 41752960)
44. Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008;136(3):432-444 • A pivotal, Phase III, US registration clinical trial that established efficacy and tolerability of duloxetine for the management of FM.
45. Chappell AS, Bradley LA, Wiltse C, et al. A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med 2008;1:91-102
46. Mease PJ, Russell IJ, Kajdasz DK, et al. Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia. Semin Arthritis Rheum 2009 [Epub ahead of print]
47. Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005;32(10):1975-1985
48. Goldenberg D, Clauw DJ, Palmer RH, et al. One-year durability of response to milnacipran treatment for fibromyalgia syndrome: results of a randomized, double-blind, monotherapy extension study. Arthritis Rheum 2007;56(9 Suppl):S603
49. Rao SG. The neuropharmacology of centrally-acting analgesic medications in fibromyalgia. Rheum Dis Clin North Am 2002;28(2):235-259
50. Millan MJ. Descending control of pain. Prog Neurobiol 2002;66(6):355-474
51. Vaishnavi SN, Nemeroff CB, Plott SJ, et al. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry 2004;55(3):320-322
52. Lyrica [package insert]. Pfizer, Inc.: New York, NY; 2009
53. Cymbalta [package insert]. Eli Lilly and Company: Indianapolis, IN; 2009
54. Chappell AS, Littlejohn G, Kajdasz DK, et al. A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia. Clin J Pain 2009;25(5):365-375
55. Savella [package insert]. Forest Pharmaceuticals, Inc.: St. Louis, MO; 2009
56. Mease PJ, Palmer RH, Rao SG, et al. Improvements in fibromyalgia symptoms are sustained for 1 year with milnacipran treatment: results from a dose-controlled, extension study. Arthritis Rheum 2008;58(9 Suppl):S383
57. Arnold LM, Goldenberg DL, Stanford SB, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 2007;56(4):1336-1344 (Pubitemid 46608659)
58. Levetiracetam for treatment of pain associated with fibromyalgia. 8 February 2008. Available from: www.clinicaltrials. gov/ct2/show/NCT00254657 [Last accessed 14 July 2009]
59. Zonisamide for fibromyalgia and migraine. 11 November 2008. Available from: www.clinicaltrials.gov/show/NCT00259636 [Last accessed 14 July 2009]
60. Assessing efficacy and safety of lacosamide compared to placebo in reducing signs and symptoms of fibromyalgia syndrome. 8 July 2008. Available from: www.clinicaltrials.gov/ct2/show/NCT00401830 [Last accessed 14 July 2009]
61. Scharf MB, Hauck M, Stover R, et al. Effect of gamma-hydroxybutyrate on pain, fatigue, and the alpha sleep anomaly in patients with fibromyalgia. Preliminary report. J Rheumatol 1998;25(10):1986-1990 (Pubitemid 28459315)
62. Scharf MB, Baumann M, Berkowitz DV. The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J Rheumatol 2003;30(5):1070-1074 (Pubitemid 36529633)
63. A safety and efficacy study of Xyrem® (sodium oxybate) to treat fibromyalgia. 4 June 2009. Available from: www.clinicaltrials.gov/ct2/show/ NCT00423813 [Last accessed 15 July 2009]
64. A safety and efficacy study of Xyrem® in subjects with fibromyalgia. 4 June 2009. Available from: www.clinicaltrials.gov/ct2/show/NCT00371137 [Last accessed 15 July 2009]
65. Eszopiclone in the treatment of insomnia and fibromyalgia. 4 March 2009. Available from: www.clinicaltrials.gov/ct2/show/NCT00392041 [Last accessed 14 July 2009]
66. A multicentre trial to determine the efficacy and safety of AD-337 in the treatment of fibromyalgia. 30 September 2007. Available from: www.clinicaltrials.gov/ct2/show/NCT00377039 [Last accessed 14 July 2009]
67. Chelsea Therapeutics initiates phase II trial of droxidopa in fibromyalgia. Chelsea Therapeutics press release, 28 January 2009. Available from: www.irconnect.com/chtp/pages/news-releases.html?d=158476 [Last accessed 16 July 2009]
68. Safety and efficacy of AGN 203818 for pain associated with fibromyalgia syndrome. 23 February 2009. Available from: www.clinicaltrials.gov/ct2/show/ NCT00445705 [Last accessed 14 July 2009]
69. Efficacy of dolasetron in patients with fibromyalgia (Dolasetron). 9 January 2009. Available from: www.clinicaltrials.gov/ct2/show/NCT00820326 [Last accessed 14 July 2009]
70. Fibromyalgia study in adults. 4 June 2009. Available from: www.clinicaltrials.gov/ct2/show/NCT00256893 [Last accessed 14 July 2009]
71. Holman AJ. Treatment of fibromyalgia with the dopamine agonist ropinirole: a 14-week double-blind pilot randomized controlled trial (RCT) with 14-week blinded extension. Arthritis Rheum 2004;50(9 Suppl):S698
72. A double-blind multicenter proof of concept trial to assess the efficacy and safety of rotigotine in subjects with fibromyalgia syndrome (SP888). 20 February 2009. Available from: www.clinicaltrials.gov/ct2/show/NCT00464737 [Last accessed 14 July 2009]
73. Products & products pipeline. ErgoNex pipeline, 2008. Available from: www.ergonex.com/products.html [Last accessed 29 June 2009]
74. Cuatrecasas G, Riudavets C, Güell MA, Nadal A. Growth hormone as concomitant treatment in severe fibromyalgia associated with low IGF-1 serum levels. A pilot study. BMC Musculoskelet Disord 2007;8:119 (Pubitemid 351169916)
75. Growth hormone in neuroendocrine dysfunction with severe fibromyalgia. 6 July 2009. Available from: www.clinicaltrials.gov/ct2/show/NCT00933686 [Last accessed 14 July 2009]
76. Bennett RM, Clark SC, Walczyk J. A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 1998;104(3):227-231 (Pubitemid 28163166)
77. Jones KD, Burckhardt CS, Deodhar AA, et al. A six-month randomized controlled trial of exercise and pyridostigmine in the treatment of fibromyalgia. Arthritis Rheum 2008;58(2):612-622 (Pubitemid 351294900)
78. Testing mestinon and exercise in fibromyalgia. 12 August 2008. Available from: www.clinicaltrials.gov/ct2/show/NCT00535587 [Last accessed 15 July 2009]
79. Efficacy and safety of an oral growth hormone drug in the treatment of fibromyalgia. 6 April 2009. Available from: www.clinicaltrials.gov/ct2/show/ NCT00116129 [Last accessed 14 July 2009]
80. GW679769 in fibromyalgia. 13 October 2008. Available from: www.clinicaltrials.gov/ct2/show/NCT00264628 [Last accessed 14 July 2009]
81. Armodafinil for fibromyalgia fatigue. 29 June 2009. Available from: www.clinicaltrials.gov/ct2/show/NCT00568919 [Last accessed 15 July 2009]
82. An eight week, double-blind efficacy study of armodafinil augmentation to alleviate fibromyalgia fatigue. 29 June 2009. Available from: www.clinicaltrials.gov/ct2/show/NCT00678691 [Last accessed 15 July 2009]
83. Comparative efficacy and tolerability of quetiapine XR and amitriptyline in the treatment of fibromyalgia. 10 November 2008. Available from: www.clinicaltrials.gov/ct2/show/NCT00766350 [Last accessed 15 July 2009]
84. Hidalgo J, Rico-Villademoros F, Calandre EP. An open-label study of quetiapine in the treatment of fibromyalgia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(1):71-77 (Pubitemid 44959248)
85. Quetiapine compared with placebo in the management of fibromyalgia. 29 January 2009;. Available from: www.clinicaltrials.gov/ct2/show/NCT00710918 [Last accessed 15 July 2009]
86. Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. J Pain 2008;9(2):164-173
87. Nabilone versus amitriptyline in improving quality of sleep in patients with fibromyalgia. 16 May 2007. Available from: www.clinicaltrials.gov/ct2/show/ NCT00381199 [Last accessed 15 July 2009]
88. Pipex Pharmaceuticals' oral flupirtine receives IRB approval to initiate phase II clinical trial for fibromyalgia. Adeona press release, 7 October 2008. Available from: www.adeonapharma.com/investors.php?pageID=19&newsID=54[Last accessed 15 July 2009]
89. Stoll AL. Fibromyalgia symptoms relieved by flupirtine: an open-label case series. Psychosomatics 2000;41(4):371-372
90. First results for Phase IIa data of UCB's lacosamide for treatment of fibromyalgia. UCB press release, 24 June 2008. Available from: www.ucb.com/media-room/newsdetail/?det=1230763&selectyear= 2008&select-archive=all [Last accessed 16 July 2009]
91. Pardi D, Black J. γ-Hydroxybutyrate/sodium oxybate: neurobiology, and impact on sleep and wakefulness. CNS Drugs 2006;20(12):993-1018 (Pubitemid 44912708)
92. Moldofsky H. Sleep and fibrositis syndrome. Rheum Dis Clin North Am 1989;15(1):91-103
93. Jazz Pharmaceuticals and UCB announce positive phase III results for sodium oxybate (JZP-6) in fibromyalgia. Jazz press release, 20 November 2008. Available from: http://investor.jazzpharma.com/phoenix. zhtml?c=210227&p= irol-newsArticle&ID=1228911&highlight=fibromyalgia [Last accessed 16 July 2009]
94. Jazz Pharmaceuticals and UCB announce second phase III study of sodium oxybate in patients with fibromyalgia meets primary endpoints. Jazz press release, 24 June 2009. Available from: http://investor.jazzpharma. com/phoenix.zhtml?c=210227&p=irol-newsArticle&ID=1302038&highlight [Last accessed 16 July 2009]
95. Moldofsky H, Lue FA, Mously C, et al. The effect of zolpidem in patients with fibromyalgia: a dose ranging, double blind, placebo controlled, modified crossover study. J Rheumatol 1996;23(3):529-533 (Pubitemid 26101596)
96. Rothschild BM. Zolpidem efficacy in fibromyalgia. J Rheumatol 1997;24(5):1012-1013
97. Grönblad M, Nykänen J, Konttinen Y, et al. Effect of zopiclone on sleep quality, morning stiffness, widespread tenderness and pain and general discomfort in primary fibromyalgia patients. A double-blind randomized trial. Clin Rheumatol 1993;12(2):186-191 (Pubitemid 23246750)
98. Drewes AM, Andreasen A, Jennum P, Nielsen KD. Zopiclone in the treatment of sleep abnormalities in fibromyalgia. Scand J Rheumatol 1991;20(4):288-293
99. Dwight MM, Arnold LM, O'Brien H, et al. An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics 1998;39(1):14-17 (Pubitemid 28152592)
100. Sayar K, Aksu G, Ak I, Tosun M. Venlafaxine treatment of fibromyalgia. Ann Pharmacother 2003;37(11):1561-1565
101. Zijlstra TR, Barendregt PJ, van de Laar MA. Venlafaxine in fibromyalgia: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum 2002;46(9 Suppl):S105
102. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. 25 November 2008. Available from: www.clinicaltrials.gov/ct2/show/NCT00696787 [Last accessed 16 July 2009]
103. Study evaluating DVS SR in patients with fibromyalgia syndrome. 4 December 2007. Available from: www.clinicaltrials.gov/ct2/show/NCT00424892 [Last accessed 16 July 2009]
104. Sosei announces completion of Phase II trial of AD 337 in fibromyalgia syndrome. Sosei press release, 18 September 2007. Available from: www.sosei.com/en/news/pdf/PR-20070918-e.pdf [Last accessed 16 July 2009]
105. Arnold L, Chatamra K, Hirsch I, Stoker M. An 8-week, randomized, double-blind, placebo-controlled, multi-center study of esreboxetine administered once daily in patients with fibromyalgia. Arthritis Rheum 2008;59(9 Suppl):S434
106. Pfizer discontinues development of two phase 3 compounds. Pfizer press release, 24 February 2009. Available from: www.pfizer.com/news/press-releases/ pfizer-press-releases.jsp [Last accessed 16 July 2009]
107. Boyd RE. Alpha2-adrenergic receptor agonists as analgesics. Curr Top Med Chem 2001;1(3):193-197
108. Muller W, Fiebich BL, Stratz T. New treatment options using 5-HT3 receptor antagonists in rheumatic diseases. Curr Top Med Chem 2006;6(18):2035-2042 (Pubitemid 44524476)
109. Seidel MF, Weinreich GF, Stratz T, Muller W. 5-HT3 receptor antagonists regulate autonomic cardiac dysfunction in primary fibromyalgia syndrome. Rheumatol Int 2007;27(11):1025-1030 (Pubitemid 47246595)
110. Reitblat T, Zamir D, Polishchuck I, et al. Patients treated by tegaserod for irritable bowel syndrome with constipation showed significant improvement in fibromyalgia symptoms. A pilot study. Clin Rheumatol 2009;28(9):1079-1082
111. Tegaserod maleate (marketed as Zelnorm). 30 April 2009. Available from: www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm051284.html [Last accessed 15 July 2009]
112. Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 2005;52(8):2495-2505
113. Pramipexole ER vs. placebo in fibromyalgia. 20 November 2008. Available from: www.clinicaltrials.gov/ct2/show/NCT00689052 [Last accessed 14 July 2009]
114. UCB announces top-line outcomes for proof-of-concept studies. UCB press release, 20 February 2009. Available from: www.ucb.com/media-room/newsdetail/? det=1292262&select-year=2009&select-archive=all [Last accessed 16 July 2009]
115. Adis R&D Insight [database online]. Terguride. Available from: http://www.adisinsight.com [Last accessed 29 June 2009]
116. Jones KD, Deodhar P, Lorentzen A, et al. Growth hormone perturbations in fibromyalgia: a review. Semin Arthritis Rheum 2007;36(6):357-379 (Pubitemid 46779123)
117. Coudore-Civiale MA, Courteix C, Eschalier A, Fialip J. Effect of tachykinin receptor antagonists in experimental neuropathic pain. Eur J Pharmacol 1998;361(2-3):175-184 (Pubitemid 29000971)
118. Dinges DF, Arora S, Darwish M, Niebler GE. Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss. Curr Med Res Opin 2006;22(1):159-167 (Pubitemid 43106919)
119. Schaller JL, Behar D. Modafinil in fibromyalgia treatment. J Neuropsychiatry Clin Neurosci 2001;13(4):530-531
120. Pachas WN. Modafinil for the treatment of fatigue of fibromyalgia. J Clin Rheumatol 2003;9(4):282-285
121. Schwartz TL, Rayancha S, Rashid A, et al. Modafinil treatment for fatigue associated with fibromyalgia. J Clin Rheumatol 2007;13(1):52 (Pubitemid 46213848)
122. Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry 2002;63(Suppl 13):5-11 (Pubitemid 35471364)
123. A study of quetiapine fumarate sustained release in major depression with comorbid fibromyalgia syndrome. 5 April 2009. Available from: www.clinicaltrials.gov/ct2/show/NCT00675896 [Last accessed 15 July 2009]
124. Agarwal N, Pacher P, Tegeder I, et al. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 2007;10(7):870-879 (Pubitemid 47013432)
125. Supporting effect of dronabinol on behavioral therapy in fibromyalgia and chronic back pain. 13 September 2005. Available from: www.clinicaltrials.gov/ ct2/show/NCT00176163 [Last accessed 15 July 2009]
126. Giesecke T, Williams DA, Harris RE, et al. Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum 2003;48(10):2916-2922 (Pubitemid 37280621)
127. Müller W, Schneider EM, Stratz T. The classification of fibromyalgia syndrome. Rheumatol Int 2007;27(11):1005-1010
128. Fuller DE, Hornfeldt CS, Kelloway JS, et al. The Xyrem risk management program. Drug Saf 2004;27(5):293-306
129. Wood PB, Holman AJ. An elephant among us: the role of dopamine in the pathophysiology of fibromyalgia. J Rheumatol 2009;36(2):221-224
130. Buskila D, Sarzi-Puttini P, Ablin JN. The genetics of fibromyalgia syndrome. Pharmacogenomics 2007;8(1):67-74